Hormonal
Mono- and multireceptor agonists combining proglucagon-derived peptides enhance efficacy in managing obesity, diabetes, and conditions affecting the kidneys, liver, and heart.
New combination therapies that target multiple receptors (e.g., GLP-1/GIP, GLP-1/Glucagon) are showing enhanced efficacy for managing obesity, diabetes, and cardiometabolic conditions. Discuss these advanced options with your healthcare provider if standard treatments are insufficient.
The therapeutic landscape is advancing with mono- and multireceptor agonists that combine proglucagon-derived peptides or include peptides like glucose-dependent insulinotropic polypeptide and amylin, enhancing efficacy in managing obesity, diabetes, and conditions affecting the kidneys, liver, and heart.
Why this rating
Described as 'advancing' and 'enhancing efficacy', but specific clinical trial data for all combinations may not be as extensive as GLP-1 monotherapy.
Source
Proglucagon-derived peptides: human physiology and therapeutic potential
Lærke S. Gasbjerg et al. · Physiological Reviews · 2025
DOI 10.1152/physrev.00057.2024
More from this paper
- GLP-1 receptor agonists lower plasma glucose and suppress appetite, providing significant benefits for glycemic control and weight loss in type 2 diabetes and obesity.Strong
- Glucagon regulates glucose and amino acid homeostasis and counters hypoglycemia.Strong
- GLP-2 analogs are effectively used in the management of short bowel syndrome, reducing the need for parenteral support and improving patient quality of life.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →